Celiac Disease - Pipeline Review, H1 2014

Global Markets Direct
April 30, 2014
79 Pages - GMD12042
$2,000.00

Summary

Global Markets Direct’s, ‘Celiac Disease - Pipeline Review, H1 2014’, provides an overview of the Celiac Disease’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Celiac Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Celiac Disease and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Celiac Disease
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Celiac Disease and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Celiac Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Celiac Disease pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Celiac Disease
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Celiac Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

'

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Celiac Disease Overview 8
Therapeutics Development 9
Pipeline Products for Celiac Disease - Overview 9
Pipeline Products for Celiac Disease - Comparative Analysis 10
Celiac Disease - Therapeutics under Development by Companies 11
Celiac Disease - Therapeutics under Investigation by Universities/Institutes 13
Celiac Disease - Pipeline Products Glance 14
Clinical Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
Celiac Disease - Products under Development by Companies 17
Celiac Disease - Products under Investigation by Universities/Institutes 19
Celiac Disease - Companies Involved in Therapeutics Development 20
BioLineRx, Ltd. 20
Alba Therapeutics Corporation 21
ActogeniX NV 22
Alvine Pharmaceuticals, Inc. 23
Avaxia Biologics, Inc. 24
Provid Pharmaceuticals, Inc. 25
Dr. Falk Pharma GmbH 26
Zedira GmbH 27
ImmusanT, Inc. 28
Calypso Biotech SA 29
Celiac Disease - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Target 31
Assessment by Mechanism of Action 34
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 42
larazotide acetate - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
latiglutenase - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
BL-7010 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Nexvax-2 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Cell Therapy for Celiac Disease - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
ERW1041E - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
AVX-176 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
ZED-101 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
CALY-002 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
ZED-1227 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
ZED-1219 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
ZED-1098 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Second Generation Proteases - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
tTG Inhibitors - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Nexvax-3 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Synthetic Peptide Targeting DQ2/DQ8 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
ZED-754 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
HLA-DQ2 Blockers - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Celiac Disease - Recent Pipeline Updates 62
Celiac Disease - Dormant Projects 68
Celiac Disease - Product Development Milestones 69
Featured News & Press Releases 69
Feb 11, 2014: Alba Therapeutics Announces Positive Results of Phase IIb Trial in Celiac Disease 69
Oct 29, 2013: Alvine Pharmaceuticals Doses First Patient in Phase 2b Trial for ALV003 in Celiac Disease 69
Aug 06, 2013: ImmusanT Initiates Study at Joslin Diabetes Center to Investigate Relationship Between Celiac Disease and Type 1 Diabetes 70
Apr 19, 2013: ImmusanT’s Epitope-specific Immunotherapy For Celiac Disease Informs Potential Of Vaccines Against Other Autoimmune Diseases 71
Sep 05, 2012: Alvine Pharma's ALV003 Receives Fast Track Designation From FDA For Treatment Of Celiac Disease 72
Sep 04, 2012: ImmusanT Initiates Clinical Trials Of Nexvax2 Therapeutic Vaccine For Celiac Disease 72
May 22, 2012: Alvine Presents Phase IIa Trial Results Of ALV003 In Celiac Disease Patients At 2012 Digestive Diseases Week Meeting 73
May 01, 2012: Alba Gains Exclusive Rights To Patient Reported Outcome Questionnaire For Patients With Celiac Disease 74
Jan 11, 2012: Microtest Laboratories To Manufacture ImmusanT's Nexvax2 Immunotherapeutic Vaccine For Expected Clinical Trial 75
Oct 24, 2011: Alvine Pharmaceuticals Presents Additional Efficacy Data From Phase IIa Trial of ALV003 in Celiac Disease Patients 75
Appendix 78
Methodology 78
Coverage 78
Secondary Research 78
Primary Research 78
Expert Panel Validation 78
Contact Us 79
Disclaimer 79

List of Tables
Number of Products under Development for Celiac Disease, H1 2014 9
Number of Products under Development for Celiac Disease - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 12
Number of Products under Investigation by Universities/Institutes, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Development, H1 2014 15
Comparative Analysis by Unknown Stage Development, H1 2014 16
Products under Development by Companies, H1 2014 17
Products under Development by Companies, H1 2014 (Contd..1) 18
Products under Investigation by Universities/Institutes, H1 2014 19
Celiac Disease - Pipeline by BiolineRx, Ltd., H1 2014 20
Celiac Disease - Pipeline by Alba Therapeutics Corporation, H1 2014 21
Celiac Disease - Pipeline by ActogeniX NV, H1 2014 22
Celiac Disease - Pipeline by Alvine Pharmaceuticals, Inc., H1 2014 23
Celiac Disease - Pipeline by Avaxia Biologics, Inc., H1 2014 24
Celiac Disease - Pipeline by Provid Pharmaceuticals, Inc., H1 2014 25
Celiac Disease - Pipeline by Dr. Falk Pharma GmbH, H1 2014 26
Celiac Disease - Pipeline by Zedira GmbH, H1 2014 27
Celiac Disease - Pipeline by ImmusanT, Inc., H1 2014 28
Celiac Disease - Pipeline by Calypso Biotech SA, H1 2014 29
Assessment by Monotherapy Products, H1 2014 30
Number of Products by Stage and Target, H1 2014 33
Number of Products by Stage and Mechanism of Action, H1 2014 36
Number of Products by Stage and Route of Administration, H1 2014 38
Number of Products by Stage and Molecule Type, H1 2014 41
Celiac Disease Therapeutics - Recent Pipeline Updates, H1 2014 62
Celiac Disease - Dormant Projects, H1 2014 68

List of Figures
Number of Products under Development for Celiac Disease, H1 2014 9
Number of Products under Development for Celiac Disease - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 11
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Products, H1 2014 15
Assessment by Monotherapy Products, H1 2014 30
Number of Products by Top 10 Target, H1 2014 31
Number of Products by Stage and Top 10 Target, H1 2014 32
Number of Products by Top 10 Mechanism of Action, H1 2014 34
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 35
Number of Products by Top 10 Route of Administration, H1 2014 37
Number of Products by Stage and Top 10 Route of Administration, H1 2014 38
Number of Products by Top 10 Molecule Type, H1 2014 39
Number of Products by Stage and Top 10 Molecule Type, H1 2014 40

$2,000.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Custom Research

Need a custom report
tailored to your goals and budget? 

E-mail us your project outline
or call Client Services to speak
with your industry analyst.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Discount Codes

Request Discount Codes
for reports of interest to you.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax